1700633961
1700633962
[11] Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int, 1995, 48(5)
:1600-1604.
1700633963
1700633964
[12] Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol, 2007, 18(6)
:1899-1904.
1700633965
1700633966
[13] Fritsche L, Budde K, Färber L, et al. Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant, 1999, 14(4)
:1036-1038.
1700633967
1700633968
[14] Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int, 2001, 59(4)
:1484-1490.
1700633969
1700633970
[15] Schieppati A, Perna A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev, 2004, 18(4)
:CD004293.
1700633971
1700633972
[16] Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant, 2008, 23(6)
:1926-1930.
1700633973
1700633974
[17] Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology, 2007, 12(6)
:576-581.
1700633975
1700633976
[18] Praga M, Barrio V, Juárez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int, 2007, 71(9)
:924-930.
1700633977
1700633978
[19] Li X, Lv R, He Q, Li H, et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol, 2008, 21(4)
:584-591.
1700633979
1700633980
[20] E Burgess. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl, 1999, 70
:s26-s32.
1700633981
1700633982
[21] J. Stewart Cameron. Focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant, 2003, 18
:vi45-vi51.
1700633983
1700633984
[22] Korbet SM. Primary focal segmental glomerulosclerosis. In: Brady R, Wilcox C, editors. Therapy in Nephrology and Hypertension: A companion to brenner and Rector’s the kidney. Philadelphia: Saunders, 2003, 223-236.
1700633985
1700633986
[23] Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant, 1993, 8(12)
:1326-1332.
1700633987
1700633988
[24] Alexopoulos E, Stangou M, Papagianni A, et al. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant, 2000, 15(9)
:1348-1356.
1700633989
1700633990
[25] Cattran D, Appel G, Hebert L, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int, 1999, 56(6)
:2220-2226.
1700633991
1700633992
[26] Meyrier A, Noel L, Auriche P, et al. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int, 1994, 45(5)
:1446-1456.
1700633993
1700633994
[27] Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol, 2004, 62(6)
:405-411.
1700633995
1700633996
[28] Xia Z, Liu G, Gao Y, et al. FK506 in the treatment of children with nephrotic syndrome of different pathological types. Clin Nephrol, 2006, 66(2)
:85-88.
1700633997
1700633998
[29] Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol, 2006, 1(1)
:109-116.
1700633999
1700634000
[30] Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol, 2008, 23(3)
:481-485.
1700634001
1700634002
（李夏玉 徐莹）
1700634003
1700634004
1700634005
1700634006
1700634008
内科学新进展 第七章 多器官功能障碍综合征
1700634009
1700634010
摘 要 多脏器功能障碍综合征（MODS）是指机体遭受严重创伤、休克、感染等急性损伤24h后，同时或序贯地出现两个或两个以上系统或器官功能障碍或衰竭，即急性多个器官功能障碍已不能维持内环境稳定的临床综合征。全身炎症反应综合征（SIRS）的症状是MODS的主要临床特征，表现为继发于各种打击全身持续高代谢、高动力循环状态及过度的炎症反应。对于MODS治疗，主要措施是针对器官功能的有效支持。现代的免疫疗法和CRRT技术等方法体现了防治结合的原则，取得一定的效果。
[
上一页 ]
[ :1.700633961e+09 ]
[
下一页 ]